The specter of generic competition has consistently Pharma loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of similar medicinal portfolios. While early years saw significant returns, the patent lapse has opened the path for discounted alternatives, possibly diminishing revenue and posing a genuine